QIAGEN and Zymark Announce Strategic Alliance

Combination of Automation Components Addresses Fully Automated,

Integrated and Ultra High-Throughput Environments



Apr 04, 2001, 01:00 ET from QIAGEN, N.V.

    VENLO, Netherlands and HOPKINTON, Mass., April 4 /PRNewswire/ --
 QIAGEN, N.V. (Nasdaq:   QGENF; Neuer Markt: QIA; Easdaq: QGEN) and Zymark
 Corporation today announced that they have entered into a strategic alliance
 addressing the use of ultra high-throughput sample and liquid handling
 automation. The alliance will focus on uses of such instrumentation for
 nucleic acid handling and purification as well as for QIAGEN's proprietary
 protein expression and purification technology.
     QIAGEN develops and markets liquid handling platforms, which automate the
 Company's market and technology leading nucleic acid handling, separation and
 purification consumables. Zymark has created leading solutions for the
 integration of such systems into fully integrated solutions for ultra
 high-throughput applications.
     The companies intend to develop and launch systems which will combine
 QIAGEN's BioRobot(TM) automated instrumentation platforms with Zymark's
 RapidPlate(TM) 96-well and 384-well pipetting solutions and Zymark's
 Staccato(TM) and Twister(TM) systems to address the rapidly expanding need for
 ultra high-throughput nucleic acid handling, separation and purification
 solutions in the genomics markets.
     Under the terms of the agreement, Zymark will supply its ultra
 high-throughput automation technologies to QIAGEN, and QIAGEN will market to
 its customers the Zymark technologies in combination with QIAGEN's broad
 portfolio of market and technology-leading nucleic acid purification
 consumable and instrumentation technologies via QIAGEN's extensive marketing
 organization.
     QIAGEN and Zymark also intend to enter into research and development
 programs to expand the uses of the combination of each company's
 instrumentation components with QIAGEN' nucleic acid handling, separation and
 purification consumable technologies.
     "This alliance significantly increases the reach of our leading automation
 solutions in the field of ultra high-throughput nucleic acid purification with
 a leading, and what we believe to be, exceptionally powerful technology
 platform," said Dr. Metin Colpan, Chief Executive Officer of QIAGEN. "The
 alliance with Zymark expands the reach of our nucleic acid handling,
 separation and purification technologies into the highest throughput
 environments in genomics by leveraging Zymark's components and integration
 solutions. We are pleased to make this expansion in partnership with Zymark, a
 leader in the field of laboratory automation and integration technologies. We
 believe that our customers in drug development and genomics will find great
 benefits in this seamless integration of QIAGEN's BioRobot products and
 Zymark's automation technologies with a broad portfolio of QIAGEN consumables.
 The integrated, complete solutions address the needs in the rapidly growing,
 ultra high-throughput market segment by significantly increasing the
 throughput and cost-effectiveness for the handling, extraction and
 purification of samples for fully integrated, ultra high-throughput genetic
 analysis applications as increasingly required in genomics."
     "QIAGEN is a recognized world leader for providing innovative technologies
 and products for the separation, purification and handling of nucleic acids.
 We are pleased that QIAGEN has chosen to integrate its highly optimized liquid
 handling solutions into Zymark's liquid handling environments and leverage our
 robotic technologies for the rapidly growing area of ultra high-throughput
 applications," stated Zymark Corporation President and CEO, Kevin Hrusovsky.
 "QIAGEN and Zymark's collaboration to integrate chemistries and automation
 represents a significant opportunity to further advance the throughput of
 nucleic acid purification, and ensures that QIAGEN's customer base will
 realize maximum benefit from the utilization of these powerful technologies."
 
     About QIAGEN
     QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany,
 the United States, Japan, the United Kingdom, Switzerland, France, Italy,
 Australia and Canada, believes it is the world's leading provider of
 innovative enabling technologies and products for the separation, purification
 and handling of nucleic acids. The Company has developed a comprehensive
 portfolio of more than 300 proprietary, consumable products for nucleic acid
 separation, purification and handling, nucleic acid amplification, as well as
 automated instrumentation, synthetic nucleic acid products and related
 services. QIAGEN's products are sold in more than 42 countries throughout the
 world to academic research markets and to leading pharmaceutical and
 biotechnology companies. In addition, the Company is positioning its products
 for sale into developing commercial markets, including DNA sequencing and
 genomics, nucleic acid-based molecular diagnostics, and genetic vaccination
 and gene therapy. QIAGEN employs approximately 1,400 people worldwide. Further
 information on QIAGEN can be found at http://www.QIAGEN.com.
 
     About Zymark
     Zymark Corporation is a premier provider of products, technologies and
 services for laboratory applications in the rapidly growing markets of life
 science. Zymark is focused exclusively on laboratory automation and robotic
 solutions. Zymark develops, manufactures and integrates innovative scientific
 and automation technologies for high-throughput applications across the entire
 drug development pipeline, including genomics and proteomics. The company's
 products span full range of user needs from low-cost, single-function
 workstations to today's most sophisticated modular robotic systems. Further
 information on Zymark Corporation can be obtained on the Internet at
 http://www.zymark.com.
 
     Certain of the statements contained in this news release may be considered
 forward-looking statements within the meaning of Section 27A of the U.S.
 Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
 Exchange Act of 1934, as amended. To the extent that any of the statements
 contained herein relating to QIAGEN's products and markets and operating
 results are forward-looking, such statements are based on current expectations
 that involve a number of uncertainties and risks. Such uncertainties and risks
 include, but are not limited to, risks associated with the challenges of
 integrating newly-acquired businesses into QIAGEN's operations, management of
 growth and international operations (including the effects of currency
 fluctuations), variability of operating results, the commercial development of
 the DNA sequencing and genomics market, nucleic acid- based molecular
 diagnostics market, and genetic vaccination and gene therapy markets,
 competition, rapid or unexpected changes in technologies, fluctuations in
 demand for QIAGEN's products (including seasonal fluctuations), difficulties
 in successfully adapting the Company's products to integrated solutions and
 producing such products, the Company's ability to identify and develop new
 products and to differentiate its products from competitors, and the
 integration of acquisitions of technologies and businesses. For further
 information, refer to the discussion in reports that the Company has filed
 with the U.S. Securities and Exchange Commission (SEC).
 
     Contact:
     Peer M. Schatz
     Chief Financial Officer
     QIAGEN N.V.
     +49-2103-2911-702
     e-mail: p.schatz@de.QIAGEN.com
 
     Dr. Solveigh Mahler
     Investor Relations
     QIAGEN N.V.
     +49-21036-2911-710
     e-mail: s.maehler@de.QIAGEN.com
 
     Noonan/Russo Communications
     212-696-4455
     Mary Claire Bice (Investors)
     Tony Ho Loke (Media)
 
     Kevin Hrusovsky
     President and CEO
     Zymark Corporation
     508-435-9500
 
     Lynda Thomas
     Marketing Communications Manager
     Zymark Corporation
     508-435-9500
     e-mail: Lynda.Thomas@zymark.com
 
 

SOURCE QIAGEN, N.V.
    VENLO, Netherlands and HOPKINTON, Mass., April 4 /PRNewswire/ --
 QIAGEN, N.V. (Nasdaq:   QGENF; Neuer Markt: QIA; Easdaq: QGEN) and Zymark
 Corporation today announced that they have entered into a strategic alliance
 addressing the use of ultra high-throughput sample and liquid handling
 automation. The alliance will focus on uses of such instrumentation for
 nucleic acid handling and purification as well as for QIAGEN's proprietary
 protein expression and purification technology.
     QIAGEN develops and markets liquid handling platforms, which automate the
 Company's market and technology leading nucleic acid handling, separation and
 purification consumables. Zymark has created leading solutions for the
 integration of such systems into fully integrated solutions for ultra
 high-throughput applications.
     The companies intend to develop and launch systems which will combine
 QIAGEN's BioRobot(TM) automated instrumentation platforms with Zymark's
 RapidPlate(TM) 96-well and 384-well pipetting solutions and Zymark's
 Staccato(TM) and Twister(TM) systems to address the rapidly expanding need for
 ultra high-throughput nucleic acid handling, separation and purification
 solutions in the genomics markets.
     Under the terms of the agreement, Zymark will supply its ultra
 high-throughput automation technologies to QIAGEN, and QIAGEN will market to
 its customers the Zymark technologies in combination with QIAGEN's broad
 portfolio of market and technology-leading nucleic acid purification
 consumable and instrumentation technologies via QIAGEN's extensive marketing
 organization.
     QIAGEN and Zymark also intend to enter into research and development
 programs to expand the uses of the combination of each company's
 instrumentation components with QIAGEN' nucleic acid handling, separation and
 purification consumable technologies.
     "This alliance significantly increases the reach of our leading automation
 solutions in the field of ultra high-throughput nucleic acid purification with
 a leading, and what we believe to be, exceptionally powerful technology
 platform," said Dr. Metin Colpan, Chief Executive Officer of QIAGEN. "The
 alliance with Zymark expands the reach of our nucleic acid handling,
 separation and purification technologies into the highest throughput
 environments in genomics by leveraging Zymark's components and integration
 solutions. We are pleased to make this expansion in partnership with Zymark, a
 leader in the field of laboratory automation and integration technologies. We
 believe that our customers in drug development and genomics will find great
 benefits in this seamless integration of QIAGEN's BioRobot products and
 Zymark's automation technologies with a broad portfolio of QIAGEN consumables.
 The integrated, complete solutions address the needs in the rapidly growing,
 ultra high-throughput market segment by significantly increasing the
 throughput and cost-effectiveness for the handling, extraction and
 purification of samples for fully integrated, ultra high-throughput genetic
 analysis applications as increasingly required in genomics."
     "QIAGEN is a recognized world leader for providing innovative technologies
 and products for the separation, purification and handling of nucleic acids.
 We are pleased that QIAGEN has chosen to integrate its highly optimized liquid
 handling solutions into Zymark's liquid handling environments and leverage our
 robotic technologies for the rapidly growing area of ultra high-throughput
 applications," stated Zymark Corporation President and CEO, Kevin Hrusovsky.
 "QIAGEN and Zymark's collaboration to integrate chemistries and automation
 represents a significant opportunity to further advance the throughput of
 nucleic acid purification, and ensures that QIAGEN's customer base will
 realize maximum benefit from the utilization of these powerful technologies."
 
     About QIAGEN
     QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany,
 the United States, Japan, the United Kingdom, Switzerland, France, Italy,
 Australia and Canada, believes it is the world's leading provider of
 innovative enabling technologies and products for the separation, purification
 and handling of nucleic acids. The Company has developed a comprehensive
 portfolio of more than 300 proprietary, consumable products for nucleic acid
 separation, purification and handling, nucleic acid amplification, as well as
 automated instrumentation, synthetic nucleic acid products and related
 services. QIAGEN's products are sold in more than 42 countries throughout the
 world to academic research markets and to leading pharmaceutical and
 biotechnology companies. In addition, the Company is positioning its products
 for sale into developing commercial markets, including DNA sequencing and
 genomics, nucleic acid-based molecular diagnostics, and genetic vaccination
 and gene therapy. QIAGEN employs approximately 1,400 people worldwide. Further
 information on QIAGEN can be found at http://www.QIAGEN.com.
 
     About Zymark
     Zymark Corporation is a premier provider of products, technologies and
 services for laboratory applications in the rapidly growing markets of life
 science. Zymark is focused exclusively on laboratory automation and robotic
 solutions. Zymark develops, manufactures and integrates innovative scientific
 and automation technologies for high-throughput applications across the entire
 drug development pipeline, including genomics and proteomics. The company's
 products span full range of user needs from low-cost, single-function
 workstations to today's most sophisticated modular robotic systems. Further
 information on Zymark Corporation can be obtained on the Internet at
 http://www.zymark.com.
 
     Certain of the statements contained in this news release may be considered
 forward-looking statements within the meaning of Section 27A of the U.S.
 Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
 Exchange Act of 1934, as amended. To the extent that any of the statements
 contained herein relating to QIAGEN's products and markets and operating
 results are forward-looking, such statements are based on current expectations
 that involve a number of uncertainties and risks. Such uncertainties and risks
 include, but are not limited to, risks associated with the challenges of
 integrating newly-acquired businesses into QIAGEN's operations, management of
 growth and international operations (including the effects of currency
 fluctuations), variability of operating results, the commercial development of
 the DNA sequencing and genomics market, nucleic acid- based molecular
 diagnostics market, and genetic vaccination and gene therapy markets,
 competition, rapid or unexpected changes in technologies, fluctuations in
 demand for QIAGEN's products (including seasonal fluctuations), difficulties
 in successfully adapting the Company's products to integrated solutions and
 producing such products, the Company's ability to identify and develop new
 products and to differentiate its products from competitors, and the
 integration of acquisitions of technologies and businesses. For further
 information, refer to the discussion in reports that the Company has filed
 with the U.S. Securities and Exchange Commission (SEC).
 
     Contact:
     Peer M. Schatz
     Chief Financial Officer
     QIAGEN N.V.
     +49-2103-2911-702
     e-mail: p.schatz@de.QIAGEN.com
 
     Dr. Solveigh Mahler
     Investor Relations
     QIAGEN N.V.
     +49-21036-2911-710
     e-mail: s.maehler@de.QIAGEN.com
 
     Noonan/Russo Communications
     212-696-4455
     Mary Claire Bice (Investors)
     Tony Ho Loke (Media)
 
     Kevin Hrusovsky
     President and CEO
     Zymark Corporation
     508-435-9500
 
     Lynda Thomas
     Marketing Communications Manager
     Zymark Corporation
     508-435-9500
     e-mail: Lynda.Thomas@zymark.com
 
 SOURCE  QIAGEN, N.V.